Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Alzheimers Dement. 2010 May;6(3):286-90. doi: 10.1016/j.jalz.2010.03.010.

The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board.

Author information

  • 1Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium. mschmid4@its.jnj.com

Abstract

The Industry Scientific Advisory Board (ISAB) consists of representatives from the private companies and nonprofit foundations participating as sponsors of Alzheimer's Disease Neuroimaging Initiative (ADNI). Currently 21 companies are represented including pharmaceutical, imaging, and biotech concerns, and two foundations including the Alzheimer's Association. ISAB members meet regularly by teleconference or face-to-face at ADNI meetings and participate in the ADNI Core groups, all administered and organized by the Foundation for the National Institutes of Health. ISAB 'deliverables' include dissemination of information to sponsors, assisting in scientific review of protocols and results, initiation and consideration of "add-on" studies and analyses, and generation of consensus positions on industry priorities and concerns. Although positioned as an advisory body, ISAB also actively contributes to the ADNI mission of identifying biomarkers of disease progression.

Copyright 2010. Published by Elsevier Inc.

PMID:
20451878
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk